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Summary. Background:Associations between vascular disease
and ABO(H) blood groups have a long history, but no
consensus exists regarding its magnitude and significance, or
whether it relates to all disorders equally. An accurate
calculation of risk would allow direct assessment of whether
the effects of non-O status on thrombosis risk are of the
magnitude predicted by its effect on von Willebrand factor/
FVIII levels. Methods and results:We conducted a systematic
review and meta-analysis of studies reporting associations with
non-Oblood groups. This gave pooled odds ratios of 1.25 [95%
confidence interval (CI) 1.14–1.36] for myocardial infarction
(MI), 1.03 (95% CI 0.89–1.19) for angina, 1.45 (95% CI 1.35–
1.56) for peripheral vascular disease, 1.14 (95% CI 1.01–1.27)
for cerebral ischemia of arterial origin, and 1.79 (95%CI 1.56 to
2.05) for venous thromboembolism (VTE). However, restric-
tion to prospective MI studies only did not confirm the
association (OR 1.01; 95% CI 0.84–1.23), although these
studiesmayhave failed to capture early-onset disease.ForVTE,
using a combined group of OO/A2A2/A2O as index, the
combination of A1A1/A1B/BB gave an OR of 2.44 (95% CI
1.79–3.33) and A1O/ BO/A2B an OR of 2.11 (95% CI 1.66–
2.68). Conclusions: This study confirms the historical impres-
sion of linkage between some vascular disorders and non-O
blood group status. Although the odds ratios are similar to
those predicted by the effect of ABO(H) on von Willebrand
factor levels, furtherwork is required to assess risk prospectively
and to refine the effect of reducing O(H) antigen expression on
thrombosis. However, as non-O and particularly A1A1, A1B,
BB constitute a significant proportion of the population
attributable fraction of VTE, there may be a role for more
widespread adoption of ABO(H) typing in testing strategies.
Introduction
Theassociationbetween thrombosis andABO(H)bloodgroups
has a long history suggesting that non-O blood groups confer a
higher risk of myocardial infarction (MI), angina, peripheral
vascular disease (PVD), cerebral ischemia of arterial origin
(CIAO), and venous thromboembolism (VTE) than group O.
However, no consensus exists regarding whether these associ-
ations are real, what its magnitude is, whether such associations
affect all vascular disease equally, whether they result from a
protection byO(H) (or a deleterious effect of groupA), whether
the association is causal and what utility there is in including
ABO(H) as part of testing to identify those at risk.
Such a link is plausible as ABO(H) determinants occur on
factor (F) VIII and von Willebrand factor (VWF), with the
lowest VWF levels seen in those of genotype OO and the
highest in those with the least O(H) antigen expression (i.e. AA,
AB and BB) [1]. Although ABO(H) may also influence
activated protein C resistance [2], no consistent relationship
with cholesterol [3,4] or other coagulation markers [4–7] has
been proven. Thus, estimating whether the strength of associ-
ation between ABO(H) type and thrombosis is similar to that
predicted by the known relationship between VWF/FVIIIc
levels and disease would add considerable weight to the
hypothesis that these factors are causal. We have therefore
performed a systematic review and meta-analysis of the studies
reporting associations between ABO(H) blood group and MI,
angina, PVD, CIAO and VTE.
Methods
Search strategy and selection criteria
An extensive search was performed on all major electronic data
bases from inception toMay 2007:MEDLINE, EMBASE, the
Cumulative Index to Nursing and Allied Health Literature
print index (CINAHL), and Ovid OLDMEDLIINE (1950–
1965). Relevant keywords and permutations of search terms
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relating to blood group were combined with those relating to
vascular disease (Table S1). This was supplemented by using
the Web of Science data base to generate a list of articles that
cited identified original studies. In addition, we also carried out
hand searching of reference lists and recent thrombosis
conference proceedings (including the British Society for
Haematology, the British Society for Haemostasis and Throm-
bosis, The European Haematology Association and the
International Society for Haemostasis and Thrombosis).
All prospective and retrospective studies meeting the
following criteria were included: (i) a population that included
those who had been ABO(H) typed; (ii) clinical outcomes
included measures of incidences of MI, angina, PVD, CIAO
and VTE; and (iii) extractable data that defined the blood
groups as either A, B, AB andO, groupO and non-O, or group
A and non-A. Although we focused on English language
studies, studies were not excluded on the basis of language.
Data abstraction and study quality assessment
One author (PC) screened abstracts and excluded irrelevant
references and the remaining studies were retrieved in full
(Fig. S1). Subsequently, two authors independently reviewed
and extracted data on study design, patient characteristics and
outcome definitions from these studies according to a prede-
fined protocol. In addition, the quality of the studies included
in the review was also assessed using a validated generic
checklist designed for quantitative studies [8]. This checklist
included 14 criteria, which are consistent with the recommen-
dations from the Centre for Reviews and Dissemination
(CRD), and the consensus statement ofmeta-analysis reporting
observational studies in epidemiology [9,10]. Any disagreement
relating to study inclusion, data extraction or quality assess-
ment was resolved by discussion.
Statistical analysis
Meta-analysis was carried out and pooled risks of blood group
non-O relative to group O were calculated for all five outcomes
based on the random effects model [11]. All the results were
expressed as odds ratios (ORs), with values >1.0 indicating an
increased risk of the outcome associated with group non-O.
Where possible, secondary analysis was conducted to deter-
mine the risk of group A relative to O and relative to non-A
(data not shown). A2 cells have higher O(H) antigen expression
than A1 [12] and A2O and A2A2 groups have the lowest of all
non-O FVIII levels [13]. Correspondingly, to determine the
effect of the least expression of the O(H) antigen (and
potentially the highest FVIII/VWF levels) on thrombotic risk
we also analyzed available data coding A2 with O. Thus, the
risk associated with carriage of a combined group of OO, A2O
and A2A2 relative to heterozygote O genotypes (A1O, BO and
A2B) and also relative to a combined group of A1A1, A1B and
BB was determined for all primary outcomes.
Heterogeneity between studies was examined with standard
chi-square tests. In addition, the I2 statistic was also calculated
[14]. Where appropriate, the extent of study variables influenc-
ing the heterogeneity in the effects was explored by fittingmeta-
regression models [15]. The variables considered in the model
were: the year of publication, retrospective or prospective study
design, the presence of objective diagnosis of clinical outcome
and whether the control group was selected from a similar
population to the group with events. The association between
study size and results was examined in funnel plots by plotting
odds ratios against their standard error and asymmetry was
measured by the asymmetry coefficient [16]. Sensitivity/influ-
ence analysis was performed by repeating the meta-analysis,
but omitting one study at a time to exclude dominance of any
one study. Analyses were performed in Rev Man (Cochrane
Collaboration) and Stata version 9.0 (StataCorp LP, College
Station, TX, USA).
Results
Of 256 studies retrieved from the initial search, 59 met the
inclusion criteria and were included. Variation in the methodo-
logical quality of the studies was observed (Fig. S2). The key
limitations to MI/angina studies were not reporting result
uncertainty (12 studies) [17–28] and a lack of control for
potential population stratification (12 studies) [17,22–24,26–
33]. For PVD, no study reported result uncertainty and/or
provided detailed demographic data [21,34–40]. Studies on
CIAO were generally of good quality, although four did not
define CIAO using modern imaging [21,41–43]. For VTE
studies, the majority did not report detailed demographic data
[44–57], whilst others failed to comprehensively adjust for
potential population stratification [13,44–58], or employed an
insufficient sample size [46,50,54,55].
Myocardial infarction and angina
Of the 22 MI studies included, 5 were conducted prospec-
tively; 11 employed objective diagnosis and 14 used controls
from a comparable population (Table S2). Nine reported a
significant increase in the risk of MI with non-O
[17,18,22,23,25,30,32,33, 59], whilst one reported a reduced
risk [60]. Overall (Fig. 1), non-O was associated with an
increased risk in MI (pooled OR 1.25; 95% CI 1.14–1.36);
however, there was evidence of heterogeneity (P <0.0001),
with a moderate proportion of the total variation in the
estimated effect due to between-study heterogeneity (I2 67%).
Meta-regression revealed that the effect of blood group non-O
on MI risk was influenced by whether the studies were
conducted retrospectively or prospectively (P = 0.04), with
separate analysis showing that retrospective studies are
associated with a greater risk estimate than prospective ones
(OR 1.33, 95% CI 1.21–1.46 vs. OR 1.01, 95% CI 0.84–1.23).
The funnel plot appeared asymmetric, but analysis did not
show any significant bias due to study size. Using group O as
an index, based upon 19 studies, group A was associated with
a similar increase in MI risk (OR 1.29, 95% CI 1.16–1.45) to
that observed with non-O (Fig. 2).
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For angina, three of the eight studies were prospective
[20,21,31], four employed objective diagnosis [20,26,32,33] and
three [20,21,60] compared cases with similar controls. None
reported significant findings, and no overall effect was found
when the study findings were pooled (Fig. 1, OR 1.03, 95% CI
0.89–1.19). There was no evidence of heterogeneity (P = 0.28)
and the individual study estimates were relatively consistent
(I2 18%). Due to the small number of studies meta-regression
Fig. 1. The individual study odds ratios (with 95% confidence intervals) and the results of the meta-analysis of blood groups non-O relative to O
for myocardial infarction (MI), angina, venous thromboembolism (VTE), peripheral vascular disease (PVD) and cerebral ischemia of arterial origin
(CIAO) are shown.
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was not performed to avoid data over-fitting. Data on group A
were available in six studies and, with the exception of one [20],
none reported statistically significant findings (Fig. 2), with no
overall effect of group A relative to O observed in pooled
analysis (OR 1.09, 95% CI 0.91–1.30).
Peripheral vascular disease
Eight studies reported an increased risk of PVD with non-O
(Fig. 1), with 4 employing an objective diagnosis [35,36,39,40]
and three [21,35,38] using similar controls (Table S3). The
Fig. 2. The individual study odds ratios (with 95% confidence intervals) and the results of the meta-analysis of blood groupA relative to O for myocardial
infarction (MI), angina, venous thromboembolism (VTE), peripheral vascular disease (PVD) and cerebral ischemia of arterial origin (CIAO) are shown.
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pooled OR for the risk of PVD for non-O relative to O was
1.45 (95% CI 1.35–1.56). There was no evidence of hetero-
geneity (P = 0.93) and the findings of the individual studies
were highly consistent (I2 0%). Meta-regression was not
performed due to the small number of studies. All 8 studies
provided data on group A (Fig. 2), and a similar increase in
PVD risk was found in group A relative to O (OR 1.44;
95%CI 1.19–1.74).
Cerebral ischemia of arterial origin
Four of the seven studies with CIAO data employed an
objective diagnosis [21,41–43] (Table S4). However, although
only one reported statistically significant findings, all reported
an increased risk of CIAO. Pooling the studies (Fig. 1) showed
that non-O significantly increased the risk of CIAO (OR 1.14,
95% CI 1.01–1.27). There was no evidence of heterogeneity
(P = 0.49) and the findings of the individual studies were
highly consistent (I2 0%). Meta-regression was not carried out
to explore heterogeneity further due to the small number of
studies. Only one of the seven did not provide data on group A
(Fig. 2). The pooled OR for group A relative to O was similar
to that for non-O (OR 1.15, 95% CI 1.01–1.31).
Venous thromboembolism
Of the 21 studies included in the VTE analysis, 3 were carried
out prospectively [49,50,61], 10 employed objective diagnosis
[13,44,47–49,58,61–64] and 14 [13,45,46,50–52,54,57,58,61,63–
66] used controls from a comparable population (Table S5).
With the exception of three [45,52,57], all reported a significant
increase in VTE risk with non-O, with ORs from 1.26 to 3.92.
Overall, the pooled OR was 1.79 (95% CI 1.56–2.05),
indicating a significant increase in VTE risk associated with
non-O. However, significant heterogeneity was present
(P < 0.0001) and the findings of the individual studies were
highly inconsistent (I2 76%). Meta-regression showed that
none of the study-level variables had a significant influence on
the risk estimate. However, the funnel plot was asymmetric and
there was evidence of bias based on both the Egger weighted
regression method (P = 0.000) and Beggs rank correlation
method (P = 0.004). Based on 17 studies [13,44,45,47–
58,63,65], similar results to that for non O/O comparisons
were observed for group A relative to O (Fig. 2, pooled OR
1.63, 95% CI 1.40–1.89).
When the data were restricted to VTE subjects who also
carried factor VLeiden (FVL) [13,46,61,66], a greater impact of
non-O on VTE risk was observed, giving a pooled OR of 3.88
(95% CI 2.51–6.00).
Blood group genotypes were available from three studies
[13,44,63]. A combined group of A1O/BO/A2B was associated
with a 2.11 increased VTE risk (95% CI 1.66–2.68) when
compared with the combined OO/A2A2//A2O group. There
was no evidence of heterogeneity (P = 0.23) and the findings
of the studies were relatively consistent (I2 33%). The VTE risk
when those with the least O(H) antigen expression (a combined
group of A1B/A1A1//BB) were compared with the OO/A2A2,/
A2O group was 2.44 (95% CI 1.79–3.33). Similarly, there was
no evidence of heterogeneity (P = 0.58) and the findings of the
studies were highly consistent (I2 0%).
Sensitivity analysis
For each of the primary outcomes, sensitivity/influence
analysis showed that the results remained consistent and no
individual study appeared to significantly influence any of the
findings.
Discussion
In this study we compared non-Owith groupO, as groups AA,
BB and AB have a similar effect on circulating VWF [67],
which might indicate protection by the O(H) antigen, rather
than a thrombotic effect of a particular non-O group.
However, as some studies have found a particular effect of
group A [18,20,22], analysis of A compared with both O and
non-A (data not shown) was also performed. In both cases and
for all disorders, remarkably similar ORs were observed to that
of non-O/O comparisons, with a considerable overlap in the
95% confidence intervals.
For MI, the non-O risk is restricted to retrospective studies,
with no overall effect observed in prospective cohorts.
Although ABO(H) is determined at birth, retrospective studies
can only be performed on survivors, which could potentially
indicate a survival advantage of non-O groups after MI.
However, prospective studies may have excluded early-onset
disease, as four of the five excluded those with pre-existing
ischemic heart disease at inception [20,21,60,68]. Interestingly,
in the one study that did not [30], a significant increase in
MI was associated with non-O (OR 1.22, 95% CI 1.04–1.43).
That no increase in the risk of angina was observed either
individually, or in meta-analysis, may indicate that ABO(H)
has no effect on the pathogenesis of atheroma, but only
influences thrombus formation. The results observed may,
however, reflect the poor or relatively non-specific clinical
diagnostic criteria employed in many studies [21,25,28,33].
Despite heterogeneity between studies, the majority of VTE
investigations reported an increased VTE risk associated with
non-O, giving a pooled OR of 1.75 (95% CI 1.51–2.03). This
heterogeneity, however, was not explained by study variables,
although there is insufficient information from available
studies to exclude an effect of ethnicity. Restricting the data
to those carrying FVL [13,46,61,66], gave a greater pooled
OR of 3.88 (95% CI 2.51–6.00). However, as yet, no study
has reported any similar interaction with the prothrombin
20210A mutation [47,61]. The studies of VTE also gave an
opportunity to study whether there might be a dose-response
effect of the O(H) antigen on VTE occurrence. Using OO
genotypes (classifying A2 with O) as a baseline, the combined
group of A1A1/A1B/BB (the lowest O(H) expression), was
associated with a slightly higher VTE risk (OR 2.44, 95% CI
1.79–3.33) than heterozygote O genotypes (the combination of
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A1O/BO/A2B; OR 2.11, 95% CI 1.66–2.68). However,
perhaps resulting from the small amount of available data,
no significant increase in the risk from the A1O/BO/A2B to
the A1A1/A1B/BB group was observed (OR 1.17, 95% CI
0.86–1.58).
For PVD, we observed a pooled OR of 1.45 (95% CI 1.35–
1.56) for non-O relative to O. Interestingly, whilst only some
used objective diagnosis [35,36,39,40], or comparable controls
[21,35,38], the findings were highly consistent. For CIAO,
pooling of the small number of available studies revealed that
blood group non-O produces a small, but significant, increased
risk of CIAO (OR 1.14, 95% CI 1.01–1.27).
Arterial and venous thrombosis share a number of risk
factors/riskmarkers. In particular, higher levels of VWF/FVIII
are both risk markers and effectors of thrombus formation and
progression [69,70]. That ABO(H) status has a stronger
influence on VTE seems, at first, surprising, as VWF is a
recognized risk factor/effector for coronary heart disease [71–
73]. However, a number of more classical risk markers/
effectors are more strongly linked with the disease than VWF
[74]. Moreover, although generally associated with increasing
age, VTE occurs (and more importantly is often reported) in
younger subjects in association with pregnancy, hormonal
therapy and surgery. A stronger genetic influence on younger-
onset disease is intuitive and, as noted above, a number of the
prospective cardiovascular risk studies excluded younger-onset
disease at inception. The more marked effect of MI and CIAO
on immediate survival (and therefore the distribution of
subjects available for recruitment to retrospective studies)
may also more markedly affect VTE than MI studies. The
finding of a similar degree of risk of PVD to that of VTE is,
however, compatible with the known association of increasing
levels of VWF and the presentation and progression of PVD
[75].
Although it seems likely that FVIII levels carry an additional
risk to that explained by ABO(H) and indeed not all ABO(H)
VTE risk is explained by FVIIIc levels [44,76], to be causal the
observed difference in risk between O and non-O types should
at least be in keeping with differences in the plasma levels of
VWF/FVIII between the groups and with the degree of
thrombosis risk that these plasma levels predict. As VWF/
FVIII is part of the acute phase response, the best estimates of
the effect of ABO(H) on VWF will be obtained from subjects
sampled before disease onset. Blood group O in normal
subjects is associated with VWF antigen levels of 65.4–
102.8 IU/dL [44,76], with most studies reporting mean levels
<90 IU/dL. In group A, B and AB subjects mean values
ranging from 90–139 IU/dL [[44,76] have been reported, with a
mean for the combined non-O group of 133.9 IU/dL reported
in one study [44]. Whincup and colleagues [77] have shown that
disease-free subjects with a VWF antigen of 90–126 IU/dL
have a 1.29-fold (95%CI 0.92–1.80) increased risk of non-fatal
MI/coronary artery disease death on follow-up when com-
pared with those with levels of <90 IU/dL. Although a crude
comparison, this result is consistent with the above effect of
non-O on VWF and on the odds ratio of non-O and MI
observed in the current study. For VTE, good prospective data
using SI units are lacking. One retrospective study has shown
that VWF antigen levels of 100–124.9 IU/dL are associated
with a 1.5-fold increased risk of VTE when compared with
levels <100 IU/dL [69]. Although this is consistent with the
OR for VTE and non-O that we have observed, prospective
examination of VWF/FVIIIc levels in SI units would be
required to confirm a causal relationship between non-O
groups and VTE. The fact that we have observed a greater risk
in those with the least O(H) antigen expression would,
however, be consistent with causality.
Currently, ABO(H) determination is not universally
included as part of the suite of tests used to identify those
considered at particular risk of VTE. Although FVL and the
prothrombin 20210A mutation carry a higher relative risk
than non-O subjects, their population-attributable fraction
(PAF) in the UK is considerably smaller than that for non-
O subjects. By way of illustration, if the incidence of FVL
[2], non-O [78] and the combination group A1A1/A1B/BB
[12] is taken as 3.4%, 55.0% and 7.3%, respectively, and a
7-fold increase in VTE risk in heterozygote FVL carriers is
assumed, then the PAF for FVL would be 16.9%. By
comparison, from the current study non-O status would give
a PAF of 30.3%, with a PAF associated with the combined
group of A1A1/A1B/BB of 9.5%. This latter figure contrasts
with the prothrombin 20210A mutation, which occurs in at
most 2% of UK subjects [79] and carries a 2–5-fold relative
risk of VTE, resulting in a PAF of between 1.96 and 7.4%.
Although universal screening may not be cost- [80] or
clinically-effective, the addition of ABO(H) typing to selec-
tive screening programmes to identify those at risk with a
view to antithrombotic intervention (perhaps particularly
A1A1/A1B/BB subjects) may give useful information, both in
isolation and in combination with other routine thrombo-
philia testing.
The data included in this review span the last 45 years.
Interestingly, despite the general improvements in study
execution over that time, the publication year, the presence
or absence of objective diagnoses and the use of comparable
controls did not have significant effects on the overall
conclusions of the review. However, further work is required
to refine the risks observed, with more information from
prospective studies of MI/angina required. Moreover, the
potential for those with the least expression of the O(H) antigen
to have the highest VTE risk needs to be confirmed, with
similar genotyping studies needed to assess any parallel effect in
MI, CIAO or PVD.
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